Identification

Name
Bevantolol
Accession Number
DB01295
Type
Small Molecule
Groups
Approved
Description

Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.

Structure
Thumb
Synonyms
  • (+-)-Bevantolol
  • 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol
  • 1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol
  • 1-(3,4-Dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol
  • 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol
  • Bevantololum
Categories
UNII
34ZXW6ZV21
CAS number
59170-23-9
Weight
Average: 345.4327
Monoisotopic: 345.194008357
Chemical Formula
C20H27NO4
InChI Key
HXLAFSUPPDYFEO-UHFFFAOYSA-N
InChI
InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
IUPAC Name
1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
SMILES
COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1

Pharmacology

Indication

For the treatment of angina pectoris and hypertension.

Pharmacodynamics

Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.

Mechanism of action

Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bevantolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Bevantolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bevantolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Experimental, Illicit
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Bevantolol.Approved, Experimental, Investigational
AcepromazineBevantolol may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bevantolol.Approved
AcetohexamideBevantolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Acetylcholine.Approved
AcetyldigitoxinBevantolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinBevantolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bevantolol.Approved
AdrafinilBevantolol may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Experimental, Investigational
AlaproclateThe serum concentration of Bevantolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Bevantolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Bevantolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Bevantolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Bevantolol.Experimental
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Bevantolol.Approved
AmibegronBevantolol may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe therapeutic efficacy of Bevantolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmitrazAmitraz may increase the atrioventricular blocking (AV block) activities of Bevantolol.Vet Approved
AmitriptylineBevantolol may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Amlodipine.Approved
AmobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bevantolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmoxapineBevantolol may increase the antihypertensive activities of Amoxapine.Approved
AmrinoneThe risk or severity of hypotension can be increased when Bevantolol is combined with Amrinone.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Bevantolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Bevantolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Bevantolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
ApraclonidineBevantolol may decrease the vasoconstricting activities of Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Aranidipine.Approved, Investigational
ArbutamineBevantolol may decrease the vasoconstricting activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Arecoline.Experimental
ArformoterolBevantolol may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Bevantolol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Bevantolol.Investigational
AsenapineAsenapine may increase the antihypertensive activities of Bevantolol.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
AvanafilAvanafil may increase the hypotensive activities of Bevantolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bevantolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bevantolol.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Bevantolol is combined with Azimilide.Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
BambuterolBevantolol may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbexacloneThe serum concentration of Bevantolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Bevantolol.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Bevantolol is combined with Bencyclane.Experimental
BendazacBendazac may decrease the antihypertensive activities of Bevantolol.Experimental
BenidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Benidipine.Approved, Investigational
BenorilateBenorilate may decrease the antihypertensive activities of Bevantolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bevantolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Bevantolol.Approved
BepridilThe risk or severity of hypotension can be increased when Bevantolol is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Bevantolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Bevantolol.Experimental
BioallethrinThe risk or severity of hypotension can be increased when Bevantolol is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
BitolterolBevantolol may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BL-1020BL-1020 may increase the hypotensive activities of Bevantolol.Investigational
BopindololBopindolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
BrexpiprazoleBevantolol may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Bevantolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bevantolol.Investigational
BucindololBucindolol may increase the antihypertensive activities of Bevantolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Bevantolol.Approved, Experimental
BufuralolBufuralol may increase the orthostatic hypotensive activities of Bevantolol.Experimental, Investigational
BumadizoneBumadizone may decrease the antihypertensive activities of Bevantolol.Experimental
BunazosinBunazosin may increase the antihypertensive activities of Bevantolol.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bevantolol.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
CabergolineBevantolol may increase the vasoconstricting activities of Cabergoline.Approved
CarbamoylcholineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Bevantolol.Experimental, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Bevantolol is combined with Carboxyamidotriazole.Investigational
CarbutamideBevantolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroverineThe risk or severity of hypotension can be increased when Bevantolol is combined with Caroverine.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Bevantolol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bevantolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bevantolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Bevantolol.Experimental
ChlorpromazineBevantolol may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideBevantolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Bevantolol.Approved
CilnidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Bevantolol is combined with Cinnarizine.Approved, Investigational
CirazolineBevantolol may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolBevantolol may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Clevidipine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bevantolol.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Bevantolol.Experimental
ClozapineClozapine may increase the antihypertensive activities of Bevantolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Bevantolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Bevantolol is combined with Cyclandelate.Approved
CymarinBevantolol may increase the bradycardic activities of Cymarin.Experimental
DapiprazoleDapiprazole may increase the antihypertensive activities of Bevantolol.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Bevantolol.Investigational
DarodipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Darodipine.Experimental
DecamethoniumDecamethonium may increase the bradycardic activities of Bevantolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Bevantolol.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
DeslanosideBevantolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bevantolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DetomidineDetomidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Vet Approved
DextroamphetamineBevantolol may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DichlorvosDichlorvos may increase the bradycardic activities of Bevantolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Bevantolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
DigitoxinBevantolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinBevantolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Bevantolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Bevantolol.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bevantolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bevantolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Bevantolol.Experimental
DL-MethylephedrineDL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
DobutamineBevantolol may decrease the vasoconstricting activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Bevantolol.Approved
DopexamineBevantolol may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DotarizineThe risk or severity of hypotension can be increased when Bevantolol is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Bevantolol.Approved
DoxepinBevantolol may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineBevantolol may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DronedaroneDronedarone may increase the bradycardic activities of Bevantolol.Approved
DroperidolDroperidol may increase the antihypertensive activities of Bevantolol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bevantolol.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
DuloxetineThe serum concentration of Bevantolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bevantolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Bevantolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bevantolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bevantolol.Approved
EfonidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Efonidipine.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Bevantolol.Experimental
EperisoneThe risk or severity of hypotension can be increased when Bevantolol is combined with Eperisone.Approved, Investigational
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Nutraceutical, Withdrawn
EphedrineBevantolol may decrease the vasoconstricting activities of Ephedrine.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Epibatidine.Experimental
EpinastineBevantolol may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineBevantolol may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bevantolol.Approved
Ergoloid mesylateBevantolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBevantolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Bevantolol.Experimental
EscitalopramBevantolol may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
EtafedrineBevantolol may decrease the vasoconstricting activities of Etafedrine.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Bevantolol.Experimental
EthosuximideThe risk or severity of hypotension can be increased when Bevantolol is combined with Ethosuximide.Approved
EtilefrineBevantolol may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
EtoperidoneThe serum concentration of Bevantolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bevantolol.Investigational, Nutraceutical
ExisulindExisulind may decrease the antihypertensive activities of Bevantolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Bevantolol.Experimental
FelodipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Bevantolol.Approved
FendilineThe risk or severity of hypotension can be increased when Bevantolol is combined with Fendiline.Withdrawn
FenoprofenFenoprofen may decrease the antihypertensive activities of Bevantolol.Approved
FenoterolBevantolol may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Bevantolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bevantolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Bevantolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Bevantolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Bevantolol.Experimental
FingolimodBevantolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Bevantolol is combined with Fish oil.Approved, Nutraceutical
FloctafenineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Floctafenine.Approved, Withdrawn
FlunarizineThe risk or severity of hypotension can be increased when Bevantolol is combined with Flunarizine.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Bevantolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Bevantolol.Experimental
FluoxetineThe serum concentration of Bevantolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Bevantolol.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the hypotensive activities of Bevantolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
FluspirileneThe risk or severity of hypotension can be increased when Bevantolol is combined with Fluspirilene.Approved, Investigational
FormoterolBevantolol may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Bevantolol.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Bevantolol is combined with Gabapentin.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Bevantolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bevantolol.Approved
GallopamilThe risk or severity of hypotension can be increased when Bevantolol is combined with Gallopamil.Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bevantolol.Approved, Investigational, Nutraceutical
GitoformateBevantolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideBevantolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideBevantolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBevantolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBevantolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneBevantolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideBevantolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideBevantolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bevantolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Bevantolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
HexobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Hexobarbital.Approved
HexoprenalineBevantolol may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineHigenamine may decrease the antihypertensive activities of Bevantolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bevantolol.Approved, Investigational
HydroxychloroquineThe metabolism of Bevantolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bevantolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bevantolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
IloperidoneBevantolol may increase the antihypertensive activities of Iloperidone.Approved
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Bevantolol.Experimental
ImipramineBevantolol may increase the antihypertensive activities of Imipramine.Approved
IndacaterolBevantolol may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineThe serum concentration of Bevantolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Bevantolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Bevantolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bevantolol.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Bevantolol.Withdrawn
Insulin HumanBevantolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkBevantolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Bevantolol.Experimental
IsoetarineBevantolol may decrease the vasoconstricting activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bevantolol.Approved, Investigational, Withdrawn
IsomethepteneBevantolol may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineBevantolol may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxicamIsoxicam may decrease the antihypertensive activities of Bevantolol.Withdrawn
IsoxsuprineBevantolol may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Isradipine.Approved, Investigational
KebuzoneKebuzone may decrease the antihypertensive activities of Bevantolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bevantolol.Approved
LabetalolLabetalol may increase the antihypertensive activities of Bevantolol.Approved
LacidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Bevantolol is combined with Lamotrigine.Approved, Investigational
Lanatoside CBevantolol may increase the bradycardic activities of Lanatoside C.Experimental
LandiololLandiolol may increase the orthostatic hypotensive activities of Bevantolol.Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Bevantolol is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
LevomilnacipranThe serum concentration of Bevantolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
LevosalbutamolBevantolol may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bevantolol.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Bevantolol is combined with Lidoflazine.Experimental
LisdexamfetamineBevantolol may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Bevantolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Bevantolol.Experimental
LoperamideThe risk or severity of hypotension can be increased when Bevantolol is combined with Loperamide.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bevantolol.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Bevantolol is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MalathionMalathion may increase the bradycardic activities of Bevantolol.Approved, Investigational
ManidipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Manidipine.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
MedetomidineMedetomidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bevantolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bevantolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bevantolol.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Bevantolol is combined with Menthol.Approved
MephentermineBevantolol may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Bevantolol.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bevantolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bevantolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bevantolol.Approved, Investigational
MetahexamideBevantolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Withdrawn
MetaraminolBevantolol may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethacholineBevantolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bevantolol.Investigational
MethohexitalThe serum concentration of Bevantolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the antihypertensive activities of Bevantolol.Approved, Investigational
MethoxamineBevantolol may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineBevantolol may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Bevantolol is combined with Methsuximide.Approved
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bevantolol.Approved, Investigational
MethylergometrineBevantolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinBevantolol may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Bevantolol.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Bevantolol is combined with Mibefradil.Investigational, Withdrawn
MidodrineBevantolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Bevantolol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Bevantolol.Approved
MirabegronBevantolol may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Bevantolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Bevantolol.Investigational
MofebutazoneMofebutazone may decrease the antihypertensive activities of Bevantolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Bevantolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bevantolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Bevantolol.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bevantolol.Approved
NaftopidilThe risk or severity of hypotension can be increased when Bevantolol is combined with Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Bevantolol.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bevantolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
NicardipineNicardipine may increase the antihypertensive activities of Bevantolol.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Bevantolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bevantolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Bevantolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bevantolol.Approved
NiguldipineBevantolol may increase the antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Bevantolol is combined with Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bevantolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
NorfenefrineBevantolol may decrease the vasoconstricting activities of Norfenefrine.Experimental
NortriptylineBevantolol may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinBevantolol may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineBevantolol may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineOlanzapine may increase the antihypertensive activities of Bevantolol.Approved, Investigational
OleandrinBevantolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlodaterolBevantolol may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bevantolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bevantolol.Approved
OrciprenalineBevantolol may decrease the vasoconstricting activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bevantolol.Vet Approved
OtiloniumThe risk or severity of hypotension can be increased when Bevantolol is combined with Otilonium.Experimental, Investigational
OuabainBevantolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bevantolol.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
OxyfedrineBevantolol may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bevantolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the antihypertensive activities of Bevantolol.Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Bevantolol.Experimental, Nutraceutical
ParaoxonParaoxon may increase the bradycardic activities of Bevantolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Bevantolol.Approved
ParoxetineThe serum concentration of Bevantolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
PentobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bevantolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Bevantolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Bevantolol.Approved
PeruvosideBevantolol may increase the bradycardic activities of Peruvoside.Experimental
PhendimetrazineBevantolol may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Bevantolol.Approved
PhentolamineBevantolol may increase the antihypertensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
PhenylephrineBevantolol may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineBevantolol may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bevantolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PinaveriumThe risk or severity of hypotension can be increased when Bevantolol is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
PirbuterolBevantolol may decrease the vasoconstricting activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Bevantolol.Experimental
PizotifenBevantolol may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Bevantolol.Experimental
PractololPractolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Bevantolol.Experimental, Investigational
PrazosinPrazosin may increase the antihypertensive activities of Bevantolol.Approved
PrenalterolBevantolol may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Bevantolol is combined with Prenylamine.Withdrawn
PrimaquineThe metabolism of Bevantolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bevantolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaterolBevantolol may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Bevantolol.Experimental
PromazinePromazine may increase the antihypertensive activities of Bevantolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bevantolol.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PropafenoneThe serum concentration of Bevantolol can be increased when it is combined with Propafenone.Approved
PropericiazineBevantolol may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Bevantolol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bevantolol.Vet Approved
PropiverineBevantolol may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropranololPropranolol may increase the orthostatic hypotensive activities of Bevantolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Bevantolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Bevantolol.Experimental
ProscillaridinBevantolol may increase the bradycardic activities of Proscillaridin.Experimental
ProtokylolBevantolol may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bevantolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bevantolol.Approved, Investigational
QuetiapineQuetiapine may increase the antihypertensive activities of Bevantolol.Approved
QuinidineBevantolol may increase the antihypertensive activities of Quinidine.Approved, Investigational
RacepinephrineBevantolol may increase the antihypertensive activities of Racepinephrine.Approved
RactopamineBevantolol may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bevantolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bevantolol.Approved
ReproterolBevantolol may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineReserpine may increase the hypotensive activities of Bevantolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Bevantolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Bevantolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bevantolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Bevantolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineBevantolol may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolBevantolol may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Bevantolol.Approved, Investigational
RitobegronBevantolol may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineBevantolol may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RivastigmineBevantolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Withdrawn
RomifidineRomifidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Vet Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
SalbutamolBevantolol may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Bevantolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Vet Approved
SalmeterolBevantolol may decrease the vasoconstricting activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bevantolol.Approved
SecobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Bevantolol is combined with Seletracetam.Investigational
SemapimodSemapimod may decrease the antihypertensive activities of Bevantolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Bevantolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Bevantolol.Investigational
SertralineThe serum concentration of Bevantolol can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the hypotensive activities of Bevantolol.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Bevantolol.Approved
SolabegronBevantolol may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Bevantolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bevantolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Bevantolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bevantolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Bevantolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Bevantolol.Experimental
SynephrineBevantolol may decrease the vasoconstricting activities of Synephrine.Experimental
TacrineTacrine may increase the bradycardic activities of Bevantolol.Investigational, Withdrawn
TadalafilTadalafil may increase the hypotensive activities of Bevantolol.Approved, Investigational
TafenoquineThe metabolism of Bevantolol can be decreased when combined with Tafenoquine.Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Bevantolol.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Bevantolol.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Bevantolol.Investigational
TenidapTenidap may decrease the antihypertensive activities of Bevantolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Bevantolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bevantolol.Vet Approved
TerazosinTerazosin may increase the antihypertensive activities of Bevantolol.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Bevantolol.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bevantolol.Approved
TerodilineThe risk or severity of hypotension can be increased when Bevantolol is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Bevantolol.Experimental
TetrahydropalmatineThe risk or severity of hypotension can be increased when Bevantolol is combined with Tetrahydropalmatine.Investigational
TetryzolineBevantolol may decrease the vasoconstricting activities of Tetryzoline.Approved
TheophyllineTheophylline may increase the hypotensive activities of Bevantolol.Approved
ThiamylalThe serum concentration of Bevantolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Bevantolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bevantolol.Withdrawn
ThiopentalThe serum concentration of Bevantolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineBevantolol may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Bevantolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bevantolol.Approved
TimololTimolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bevantolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
TolazamideBevantolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Bevantolol.Approved, Vet Approved
TolbutamideBevantolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Bevantolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Bevantolol.Approved, Investigational
TretoquinolBevantolol may decrease the vasoconstricting activities of Tretoquinol.Experimental
TribenosideTribenoside may decrease the antihypertensive activities of Bevantolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Bevantolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Bevantolol.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Bevantolol.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Bevantolol is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Bevantolol is combined with Trimethadione.Approved
TrimipramineBevantolol may increase the antihypertensive activities of Trimipramine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Bevantolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Bevantolol.Approved
TulobuterolBevantolol may decrease the vasoconstricting activities of Tulobuterol.Investigational
TyrothricinTyrothricin may increase the bradycardic activities of Bevantolol.Approved
UdenafilUdenafil may increase the hypotensive activities of Bevantolol.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Bevantolol.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Withdrawn
VardenafilVardenafil may increase the hypotensive activities of Bevantolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Bevantolol can be increased when it is combined with Venlafaxine.Approved
VerapamilBevantolol may increase the antihypertensive activities of Verapamil.Approved
VilanterolBevantolol may decrease the vasoconstricting activities of Vilanterol.Approved
VinpocetineThe risk or severity of hypotension can be increased when Bevantolol is combined with Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Bevantolol is combined with WIN 55212-2.Experimental
XamoterolBevantolol may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Bevantolol is combined with Ziconotide.Approved
ZileutonZileuton may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bevantolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Bevantolol.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Bevantolol.Withdrawn
ZonisamideThe risk or severity of hypotension can be increased when Bevantolol is combined with Zonisamide.Approved, Investigational
ZuclopenthixolBevantolol may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Yutaka Nomura, "Process for preparation of bevantolol hydrochloride." U.S. Patent US5382689, issued December, 1974.

US5382689
General References
  1. Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789]
External Links
Human Metabolome Database
HMDB0015409
PubChem Compound
2372
PubChem Substance
46506014
ChemSpider
2282
ChEBI
238698
ChEMBL
CHEMBL314010
Therapeutic Targets Database
DAP000897
PharmGKB
PA164743236
Wikipedia
Bevantolol
ATC Codes
C07AB06 — BevantololC07BB06 — Bevantolol and thiazides

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)137-138 °CPhysProp
logP3.00HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0137 mg/mLALOGPS
logP2.83ALOGPS
logP3.03ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area59.95 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity98.54 m3·mol-1ChemAxon
Polarizability39.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8271
Blood Brain Barrier-0.9297
Caco-2 permeable-0.6012
P-glycoprotein substrateSubstrate0.8119
P-glycoprotein inhibitor IInhibitor0.625
P-glycoprotein inhibitor IIInhibitor0.8061
Renal organic cation transporterNon-inhibitor0.6935
CYP450 2C9 substrateNon-substrate0.7741
CYP450 2D6 substrateSubstrate0.5792
CYP450 3A4 substrateSubstrate0.5727
CYP450 1A2 substrateNon-inhibitor0.6261
CYP450 2C9 inhibitorNon-inhibitor0.9068
CYP450 2D6 inhibitorNon-inhibitor0.7311
CYP450 2C19 inhibitorNon-inhibitor0.9218
CYP450 3A4 inhibitorNon-inhibitor0.6133
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9339
Ames testNon AMES toxic0.9124
CarcinogenicityNon-carcinogens0.926
BiodegradationNot ready biodegradable0.8696
Rat acute toxicity2.0966 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6187
hERG inhibition (predictor II)Inhibitor0.8681
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Methoxybenzenes
Direct Parent
Dimethoxybenzenes
Alternative Parents
Phenethylamines / Phenoxy compounds / Anisoles / Toluenes / Aralkylamines / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds
show 1 more
Substituents
Dimethoxybenzene / O-dimethoxybenzene / Phenethylamine / Anisole / Phenol ether / Phenoxy compound / Alkyl aryl ether / Aralkylamine / Toluene / 1,2-aminoalcohol
show 13 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
propanolamine (CHEBI:238698)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Hino T, Sakai K, Ichihara K, Abiko Y: Attenuation of ischaemia-induced regional myocardial acidosis by bevantolol, a beta 1-adrenoceptor antagonist, in dogs. Pharmacol Toxicol. 1989 Apr;64(4):324-8. [PubMed:2568629]
  2. Dukes ID, Vaughan Williams EM: Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365-80. [PubMed:2858236]
  3. Lofdahl CG, Svedmyr K, Svedmyr N: Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy. 1984 Jul-Aug;4(4):205-10. [PubMed:6148733]
  4. Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789]
  5. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. [PubMed:1358746]

Drug created on June 30, 2007 08:18 / Updated on July 02, 2018 17:32